Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDR | P35968 | 14/20 | 1.00 |
| ▸ | CYP3A4 | P08684 | 12/20 | 1.00 |
| ▸ | KCNH2 | Q12809 | 3/20 | 0.71 |
| ▸ | FGFR1 | P11362 | 6/20 | 0.67 |
| ▸ | RET | P07949 | 4/20 | 0.67 |
| ▸ | STK10 | O94804 | 3/20 | 0.67 |
| ▸ | MAP4K4 | O95819 | 3/20 | 0.67 |
| ▸ | PDGFRB | P09619 | 3/20 | 0.67 |
| ▸ | DDR1 | Q08345 | 3/20 | 0.67 |
| ▸ | SLK | Q9H2G2 | 3/20 | 0.67 |
| ▸ | EPHB6 | O15197 | 2/20 | 0.67 |
| ▸ | RIPK2 | O43353 | 2/20 | 0.67 |
| ▸ | ABL1 | P00519 | 2/20 | 0.67 |
| ▸ | EGFR | P00533 | 2/20 | 0.67 |
| ▸ | LCK | P06239 | 2/20 | 0.67 |
| ▸ | CSF1R | P07333 | 2/20 | 0.67 |
| ▸ | HCK | P08631 | 2/20 | 0.67 |
| ▸ | KIT | P10721 | 2/20 | 0.67 |
| ▸ | SRC | P12931 | 2/20 | 0.67 |
| ▸ | PDGFRA | P16234 | 2/20 | 0.67 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1228195 | 0.90 | KDR (0.84) | KDRCYP3A4KCNH2FGFR1RET | |
| SCHEMBL1227674 | 0.88 | KDR (0.79) | KDRCYP3A4KCNH2FGFR1RET | |
| SCHEMBL1226319 | 0.87 | KDR (0.78) | KDRCYP3A4KCNH2FGFR1RET | |
| SCHEMBL1227789 | 0.86 | KDR (0.77) | KDRCYP3A4KCNH2FGFR1RET | |
| SCHEMBL1227526 | 0.86 | KDR (0.78) | KDRCYP3A4KCNH2FGFR1RET | |
| SCHEMBL3451491 | 0.86 | KDR (0.78) | KDRCYP3A4KCNH2FGFR1RET | |
| SCHEMBL14140810 | 0.86 | KDR (0.77) | KDRCYP3A4KCNH2FGFR1RET | |
| SCHEMBL1227548 | 0.86 | KDR (0.77) | KDRCYP3A4KCNH2FGFR1RET | |
| SCHEMBL1227552 | 0.85 | KDR (0.77) | KDRCYP3A4KCNH2FGFR1RET | |
| SCHEMBL1227649 | 0.85 | KDR (0.76) | KDRCYP3A4KCNH2FGFR1RET |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1534290-B1 | NOVEL INHIBITORS OF KINASES | BRISTOL MYERS SQUIBB CO (US) | 2011-12-21 | — | — | EP | disclosed |
| EP-2280012-A2 | Pyrrolo[2,1-f][1,2,4]triazine derivatives as kinase inhibitors | Bristol-Myers Squibb Company (US) | 2011-02-02 | — | — | EP | disclosed |
| US-7820814-B2 | Inhibitors of kinases | BRISTOL-MYERS SQUIBB COMPANY (US) | 2010-10-26 | — | — | US | disclosed |
| US-20090170853-A1 | 4-(4-Fluoro-2-methyl-1H-indol-5-yloxy)-5-methylpyrrolo[2,1-f][1,2,4]triazin-6-ol; inhibit the tyrosine kinase activity of endothelial and fibroblast growth factors receptors; angiogenesis inhibitor; anticarcinogenic agent (hepatocellular cancer, colorectal cancer or non-small cell lung cancer) | BRISTOL-MYERS SQUIBB COMPANY | 2009-07-02 | — | — | US | disclosed |
| US-7521450-B2 | Inhibitors of kinases | BRISTOL-MYERS SQUIBB COMPANY (US) | 2009-04-21 | — | — | US | disclosed |
| US-20070299075-A1 | e.g. 1-[4-(4-Fluoro-2-methyl-1H-indol-5-yloxy)-5-methyl-pyrrolo[2,1-f][1,2,4]triazin-6-yloxy]-4-(aminosulfonyl)aminobutan-2-ol; inhibit the tyrosine kinase activity of endothelial and fibroblast growth factors receptors; angiogenesis inhibitor; anticarcinogenic agent | BRISTOL-MYERS SQUIBB COMPANY | 2007-12-27 | — | — | US | disclosed |
| US-6869952-B2 | Pyrrolo[2,1-f][1,2,4]triazine inhibitors of kinases | BRISTOL MYERS SQUIBB COMPANY (US) | 2005-03-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090170853-A1 | 4-(4-Fluoro-2-methyl-1H-indol-5-yloxy)-5-methylpyrrolo[2,1-f][1,2,4]triazin-6-ol; inhibit the tyrosine kinase activity of endothelial and fibroblast growth factors receptors; angiogenesis inhibitor; anticarcinogenic agent (hepatocellular cancer, colorectal cancer or non-small cell lung cancer) | FGFR1, FLT1, FLT4 | KDR 6/4885CYP3A4 683/4885KCNH2 3966/4885 |
| US-20070299075-A1 | e.g. 1-[4-(4-Fluoro-2-methyl-1H-indol-5-yloxy)-5-methyl-pyrrolo[2,1-f][1,2,4]triazin-6-yloxy]-4-(aminosulfonyl)aminobutan-2-ol; inhibit the tyrosine kinase activity of endothelial and fibroblast growth factors receptors; angiogenesis inhibitor; anticarcinogenic agent | FGFR1, FLT1, FGFR2 | KDR 9/4885CYP3A4 2215/4885KCNH2 2834/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.